Gilead-Yuhan hold Korean ‘Genvoya’ Launch Event
Gilead Sciences Korea(CEO Seung-Woo Lee) and Yuhan Corporation(CEO Jung-Hee Lee) announced that they held the product launch event for the new one-pill, combination HIV treatment ‘Genvoya(elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg, Tenofovir alafenamide 10mg)’ on the 13th.
Taking ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
